Journal of Neurology

, Volume 260, Issue 12, pp 2974–2980

Motor fluctuations and Helicobacter pylori in Parkinson’s disease

Original Communication

Abstract

The presence of Helicobacter pylori (HP) in the gastrointestinal tract may limit the absorption of levodopa. The objectives of this study were to investigate whether HP infection may affect the clinical response to levodopa as well as levodopa dose requirement in patients with Parkinson’s disease (PD) as well as to investigate whether HP infection may affect plasma levels of vitamin B12, folic acid, and homocysteine. Seventy-five patients with PD diagnosed at least 4 years ago were included. Symptom fluctuations were assessed by UPDRS-IV and the WOQ9 wearing-off-scale. Plasma levels of vitamin B12, folic acid, and homocysteine were analyzed. Screening for HP was performed with a 13C-labeled urea breath test (Diabact UBT). A propensity-matched analysis was made where each patient in the HP-infected group was matched with one patient in the non-infected group with respect to age and gender. Of the 75 included patients, 20 were HP infected (27 %). Median Hoehn & Yahr scores were 3 in both HP infected patients and the matched group (n = 20). HP-infected patients had decreased “complications of therapy” with average total UPDRS-IV score of 4.8 ± 3.0 vs. 7.7 ± 3.8 (p < 0.05), despite no significant difference in levodopa equivalent dose. Wearing-off and sleep disturbance were significantly less common in the HP group (p < 0.05). There were no differences regarding vitamin B12, folic acid, or homocysteine values. HP infection in patients with PD may result in a decreased occurrence of symptom fluctuations according to this small study. This finding may be due to altered absorption of levodopa in the gastrointestinal tract in patients with HP infection, but further studies are required.

Keywords

Parkinson’s disease Helicobacter pylori Levodopa Motor fluctuations Sleep 

References

  1. 1.
    Lewitt PA (2008) Levodopa for the treatment of Parkinson’s disease. N Engl J Med 359(23):2468–2476. doi:10.1056/NEJMct0800326 PubMedCrossRefGoogle Scholar
  2. 2.
    Nyholm D, Lennernas H (2008) Irregular gastrointestinal drug absorption in Parkinson’s disease. Expert Opin Drug Metab Toxicol 4(2):193–203. doi:10.1517/17425255.4.2.193 PubMedCrossRefGoogle Scholar
  3. 3.
    Nyholm D, Karlsson E, Lundberg M, Askmark H (2010) Large differences in levodopa dose requirement in Parkinson’s disease: men use higher doses than women. Eur J Neurol 17(2):260–266. doi:10.1111/j.1468-1331.2009.02866.x PubMedCrossRefGoogle Scholar
  4. 4.
    Pierantozzi M, Pietroiusti A, Brusa L, Galati S, Stefani A, Lunardi G, Fedele E, Sancesario G, Bernardi G, Bergamaschi A, Magrini A, Stanzione P, Galante A (2006) Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations. Neurology 66(12):1824–1829. doi:10.1212/01.wnl.0000221672.01272.ba PubMedCrossRefGoogle Scholar
  5. 5.
    Niehues M, Hensel A (2009) In-vitro interaction of l-dopa with bacterial adhesins of Helicobacter pylori: an explanation for clinical differences in bioavailability? J Pharm Pharmacol 61(10):1303–1307. doi:10.1211/jpp/61.10.0005 PubMedGoogle Scholar
  6. 6.
    Fiddian-Green RG (2007) Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations. Neurology 68(13):1085. doi:10.1212/01.wnl.0000260440.07107.99 author reply 1085PubMedCrossRefGoogle Scholar
  7. 7.
    Lyte M (2010) Microbial endocrinology as a basis for improved L-DOPA bioavailability in Parkinson’s patients treated for Helicobacter pylori. Med Hypotheses 74(5):895–897. doi:10.1016/j.mehy.2009.11.001 PubMedCrossRefGoogle Scholar
  8. 8.
    Nielsen HH, Qiu J, Friis S, Wermuth L, Ritz B (2012) Treatment for Helicobacter pylori infection and risk of Parkinson’s disease in Denmark. Eur J Neurol 19(6):864–869. doi:10.1111/j.1468-1331.2011.03643.x PubMedCrossRefGoogle Scholar
  9. 9.
    Lacy BE, Rosemore J (2001) Helicobacter pylori: ulcers and more: the beginning of an era. J Nutr 131(10):2789S–2793SPubMedGoogle Scholar
  10. 10.
    Brown LM (2000) Helicobacter pylori: epidemiology and routes of transmission. Epidemiol Rev 22(2):283–297PubMedCrossRefGoogle Scholar
  11. 11.
    Pounder RE, Ng D (1995) The prevalence of Helicobacter pylori infection in different countries. Aliment Pharmacol Ther 9(Suppl 2):33–39PubMedGoogle Scholar
  12. 12.
    Storskrubb T, Aro P, Ronkainen J, Sipponen P, Nyhlin H, Talley NJ, Engstrand L, Stolte M, Vieth M, Walker M, Agreus L (2008) Serum biomarkers provide an accurate method for diagnosis of atrophic gastritis in a general population: the Kalixanda study. Scand J Gastroenterol 43(12):1448–1455. doi:10.1080/00365520802273025 PubMedCrossRefGoogle Scholar
  13. 13.
    Graham DY, Adam E, Reddy GT, Agarwal JP, Agarwal R, Evans DJ Jr, Malaty HM, Evans DG (1991) Seroepidemiology of Helicobacter pylori infection in India. Comparison of developing and developed countries. Dig Dis Sci 36(8):1084–1088PubMedCrossRefGoogle Scholar
  14. 14.
    Graham DY, Lew GM, Klein PD, Evans DG, Evans DJ Jr, Saeed ZA, Malaty HM (1992) Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med 116(9):705–708PubMedCrossRefGoogle Scholar
  15. 15.
    Kusters JG, van Vliet AH, Kuipers EJ (2006) Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev 19(3):449–490. doi:10.1128/CMR.00054-05 PubMedCrossRefGoogle Scholar
  16. 16.
    Lehours P, Yilmaz O (2007) Epidemiology of Helicobacter pylori infection. Helicobacter 12(Suppl 1):1–3. doi:10.1111/j.1523-5378.2007.00541.x PubMedCrossRefGoogle Scholar
  17. 17.
    Malaty HM (2007) Epidemiology of Helicobacter pylori infection. Best Pract Res Clin Gastroenterol 21(2):205–214. doi:10.1016/j.bpg.2006.10.005 PubMedCrossRefGoogle Scholar
  18. 18.
    Xia HH, Talley NJ (1997) Natural acquisition and spontaneous elimination of Helicobacter pylori infection: clinical implications. Am J Gastroenterol 92(10):1780–1787PubMedGoogle Scholar
  19. 19.
    Roosendaal R, Kuipers EJ, Buitenwerf J, van Uffelen C, Meuwissen SG, van Kamp GJ, Vandenbroucke-Grauls CM (1997) Helicobacter pylori and the birth cohort effect: evidence of a continuous decrease of infection rates in childhood. Am J Gastroenterol 92(9):1480–1482PubMedGoogle Scholar
  20. 20.
    Haruma K, Okamoto S, Kawaguchi H, Gotoh T, Kamada T, Yoshihara M, Sumii K, Kajiyama G (1997) Reduced incidence of Helicobacter pylori infection in young Japanese persons between the 1970s and the 1990s. J Clin Gastroenterol 25(4):583–586PubMedCrossRefGoogle Scholar
  21. 21.
    Parsonnet J, Blaser MJ, Perez-Perez GI, Hargrett-Bean N, Tauxe RV (1992) Symptoms and risk factors of Helicobacter pylori infection in a cohort of epidemiologists. Gastroenterology 102(1):41–46 [pii]:S0016508592000362PubMedGoogle Scholar
  22. 22.
    Telaranta-Keerie A, Kara R, Paloheimo L, Harkonen M, Sipponen P (2010) Prevalence of undiagnosed advanced atrophic corpus gastritis in Finland: an observational study among 4,256 volunteers without specific complaints. Scand J Gastroenterol 45(9):1036–1041. doi:10.3109/00365521.2010.487918 PubMedCrossRefGoogle Scholar
  23. 23.
    Rees K, Stowe R, Patel S, Ives N, Breen K, Clarke CE, Ben-Shlomo Y (2011) Helicobacter pylori eradication for Parkinson’s disease. Cochrane Database Syst Rev (11):CD008453. doi:10.1002/14651858.CD008453.pub2
  24. 24.
    Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17(5):427–442PubMedCrossRefGoogle Scholar
  25. 25.
    Movement Disorder Society Task Force on Rating Scales for Parkinson’s Disease (2003) The Unified Parkinson’s Disease Rating Scale (UPDRS): status and recommendations. Mov Disord 18(7):738–750. doi:10.1002/mds.10473 CrossRefGoogle Scholar
  26. 26.
    Stacy MA, Murphy JM, Greeley DR, Stewart RM, Murck H, Meng X (2008) The sensitivity and specificity of the 9-item Wearing-off Questionnaire. Parkinsonism Relat Disord 14(3):205–212. doi:10.1016/j.parkreldis.2007.07.013 PubMedCrossRefGoogle Scholar
  27. 27.
    Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25(15):2649–2653. doi:10.1002/mds.23429 PubMedCrossRefGoogle Scholar
  28. 28.
    Evrengul H, Tanriverdi H, Kuru O, Enli Y, Yuksel D, Kilic A, Kaftan A, Kirac S, Kilic M (2007) Elevated homocysteine levels in patients with slow coronary flow: relationship with Helicobacter pylori infection. Helicobacter 12(4):298–305. doi:10.1111/j.1523-5378.2007.00505.x PubMedCrossRefGoogle Scholar
  29. 29.
    Hu XW, Qin SM, Li D, Hu LF, Liu CF (2013) Elevated homocysteine levels in levodopa-treated idiopathic Parkinson’s disease: a meta-analysis. Acta Neurol Scand 128(2):73–82. doi:10.1111/ane.12106 PubMedCrossRefGoogle Scholar
  30. 30.
    Pietroiusti A, Galante A, Magrini A, Bergamaschi A (2008) Helicobacter pylori interference with micronutrients and orally administered drugs: a new mechanism explaining its role in extragastric disorders. Mini Rev Med Chem 8(2):135–141PubMedCrossRefGoogle Scholar
  31. 31.
    Marino MC, de Oliveira CA, Rocha AM, Rocha GA, Clementino NC, Antunes LF, Oliveira RA, Martins AS, Del Puerto HL, D’Almeida V, Galdieri L, Pedroso ER, Cabral MM, Nogueira AM, Queiroz DM (2007) Long-term effect of Helicobacter pylori eradication on plasma homocysteine in elderly patients with cobalamin deficiency. Gut 56(4):469–474. doi:10.1136/gut.2006.095125 PubMedCrossRefGoogle Scholar
  32. 32.
    Sekhon J (2011) Multivariate and propensity score matching software with automated balance optimization: the matching package for R. J Stat Softw 42:1–52Google Scholar
  33. 33.
    Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K (2004) Levodopa and the progression of Parkinson’s disease. N Engl J Med 351(24):2498–2508. doi:10.1056/NEJMoa033447 PubMedCrossRefGoogle Scholar
  34. 34.
    Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang AE, Olanow CW (2010) Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 68(1):18–27. doi:10.1002/ana.22060 PubMedCrossRefGoogle Scholar
  35. 35.
    Nyholm D, Askmark H, Aquilonius SM (2011) Stalevo reduction in dyskinesia evaluation in Parkinson’s disease results were expected from a pharmacokinetic viewpoint. Ann Neurol 69(2):424. doi:10.1002/ana.22257 author reply 425PubMedCrossRefGoogle Scholar
  36. 36.
    Wong WM, Lam SK, Lai KC, Chu KM, Xia HH, Wong KW, Cheung KL, Lin SK, Wong BC (2003) A rapid-release 50-mg tablet-based 13C-urea breath test for the diagnosis of Helicobacter pylori infection. Aliment Pharmacol Ther 17(2):253–257 [pii]:1417PubMedCrossRefGoogle Scholar
  37. 37.
    Kokkola A, Kosunen TU, Puolakkainen P, Sipponen P, Harkonen M, Laxen F, Virtamo J, Haapiainen R, Rautelin H (2003) Spontaneous disappearance of Helicobacter pylori antibodies in patients with advanced atrophic corpus gastritis. APMIS 111(6):619–624PubMedCrossRefGoogle Scholar
  38. 38.
    Salomaa-Rasanen A, Kosunen TU, Mattila J, Sarna S, Rautelin H (2004) Age-dependent accuracy of Helicobacter pylori antibody assays for adults, with special emphasis on atrophic gastritis. Clin Diagn Lab Immunol 11(6):1185–1188. doi:10.1128/CDLI.11.6.1185-1188.2004 PubMedGoogle Scholar
  39. 39.
    Graham DY, Opekun AR, Yamaoka Y, Osato MS, el-Zimaity HM (2003) Early events in proton pump inhibitor-associated exacerbation of corpus gastritis. Aliment Pharmacol Ther 17(2):193–200PubMedCrossRefGoogle Scholar
  40. 40.
    Murakami K, Sato R, Okimoto T, Watanabe K, Nasu M, Fujioka T, Kodama M, Kagawa J (2003) Influence of anti-ulcer drugs used in Japan on the result of 13C-urea breath test for the diagnosis of Helicobacter pylori infection. J Gastroenterol 38(10):937–941. doi:10.1007/s00535-003-1176-x PubMedCrossRefGoogle Scholar
  41. 41.
    Varis K, Sipponen P, Laxen F, Samloff IM, Huttunen JK, Taylor PR, Heinonen OP, Albanes D, Sande N, Virtamo J, Harkonen M (2000) Implications of serum pepsinogen I in early endoscopic diagnosis of gastric cancer and dysplasia. Helsinki Gastritis Study Group. Scand J Gastroenterol 35(9):950–956PubMedCrossRefGoogle Scholar
  42. 42.
    Drake IM, Mapstone NP, Schorah CJ, White KL, Chalmers DM, Dixon MF, Axon AT (1998) Reactive oxygen species activity and lipid peroxidation in Helicobacter pylori associated gastritis: relation to gastric mucosal ascorbic acid concentrations and effect of H pylori eradication. Gut 42(6):768–771PubMedCrossRefGoogle Scholar
  43. 43.
    Lee WY, Yoon WT, Shin HY, Jeon SH, Rhee PL (2008) Helicobacter pylori infection and motor fluctuations in patients with Parkinson’s disease. Mov Disord 23(12):1696–1700. doi:10.1002/mds.22190 PubMedCrossRefGoogle Scholar
  44. 44.
    Salim AS (1993) The relationship between Helicobacter pylori and oxygen-derived free radicals in the mechanism of duodenal ulceration. Intern Med 32(5):359–364PubMedCrossRefGoogle Scholar
  45. 45.
    Lahner E, Annibale B, Delle Fave G (2009) Systematic review: Helicobacter pylori infection and impaired drug absorption. Aliment Pharmacol Ther 29(4):379–386. doi:10.1111/j.1365-2036.2008.03906.x PubMedCrossRefGoogle Scholar
  46. 46.
    Dixon M (1996) Pathological consequences of Helicobacter pylori infection. Scand J Gastroenterol Suppl 215:21PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.NeuroCenter Saint Göran HospitalStockholmSweden
  2. 2.Department of Neuroscience, NeurologyUppsala UniversityUppsalaSweden

Personalised recommendations